ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Impact of diabetes mellitus on early and midterm outcomes after transcatheter aortic valve implantation (from a multicenter registry).

Tuesday, December 17, 2013

Submitted by

Source

Source Name: American Journal of Cardiology

Source URL: http://www.ncbi.nlm.nih.gov/pubmed/24315111

Author(s)

Conrotto F, D'Ascenzo F, Giordana F, Salizzoni S, Tamburino C, Tarantini G, Presbitero P, Barbanti M, Gasparetto V, Mennuni M, Napodano M, Rossi ML, La Torre M, Ferraro G, Omedè P, Scacciatella P, Marra WG, Colaci C, Biondi-Zoccai G, Moretti C, D'Amico M,Rinaldi M, Gaita F, Marra S.

In this manuscript the authors evaluate the data from an Italian multicentre registry looking at the effect of diabetes mellitus (DM) on outcomes following transcatheter aortic valve implantations. At 30 days, patients with orally treated and insulin-treated DM demonstrated non-significant higher rates of all cause and cardiovascular death than non-diabetic patients. There was no difference with regards to safety outcomes such as acute kidney injury, vascular complications, stroke or life-threatening bleeding, between diabetic and non-diabetic patients.
Ad midterm follow up (median 400 days), and after multivariable analysis, insulin-treated DM was independently correlated with death and myocardial infarction.